Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced a final cash dividend of RMB 0.32 per share for the year ending December 31, 2024. This announcement reflects the company’s commitment to providing returns to its shareholders. The dividend will be subject to withholding tax rates depending on the residency status of shareholders, with non-resident enterprises and individuals facing a 10% tax, while mainland investors through the Stock Connect programs will incur a 20% tax. This decision underscores Fosun Pharma’s stable financial performance and its strategic focus on rewarding investors, potentially enhancing its attractiveness in the market.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company is known for its diverse range of healthcare solutions and has a significant market presence in China and internationally.
YTD Price Performance: 7.95%
Average Trading Volume: 5,063
Technical Sentiment Signal: Hold
Current Market Cap: $8.24B
For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.